Background: Li–Fraumeni and Li–Fraumeni-like syndromes (LFS/LFL), characterised by the development of multiple early onset cancers with heterogeneous tumour patterns, are associated with germline TP53 mutations. Polymorphisms in the TP53 pathway (TP53 PEX4 at codon 72, rs1042522; MDM2 SNP309, rs2279744) have modifier effects on germline TP53 mutations that may account for the individual and familial diversity of tumour patterns.
Methods and results: Four polymorphisms were analysed in a series of 135 Brazilian LFS/LFL cancer patients (32 TP53 mutation carriers and 103 wild-type subjects). We report for the first time that another polymorphism in the TP53 gene, TP53 PIN3 (rs17878362), has a strong modifier effect on germline TP53 mutations. This polymorphism, which consists of a 16 bp duplication in intron 3 (A1, non-duplicated allele; A2, duplicated allele), is associated with a difference of 19.0 years in the mean age at the first diagnosis in TP53 mutation carriers (n = 25, A1A1: 28.0 years; n = 7, A1A2: 47.0 years; p = 0.01). In addition, cancer occurrence before the age of 35 years is exclusively observed in A1A1 homozygotes. In this series, the effect of TP53 PEX4 and MDM2 SNP309 on age at diagnosis was similar to the one reported in other series and was smaller than the one of TP53 PIN3 (TP53 PIN3: difference of 19.0 years; TP53 PEX4: 8.3 years; MDM2 SNP309: 12.5 years).
Conclusion: These results suggest that TP53 PIN3 is another polymorphism in the TP53 pathway that may have a modifier effect on germline TP53 mutations and may contribute to the phenotypic diversity of germline TP53 mutations associated with LFS/LFL patients.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
▸ Additional tables are published online only at http://jmg.bmj.com/content/vol46/issue11
VM and EIP contributed equally to this work
Funding VM is supported by la Ligue Nationale Contre le Cancer (French association). This work is supported by EU FP6 program MUTp53, by la Ligue du Rhone Contre le Cancer and in part by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Edital MCT-CNPq/MS-SCTIE-DECIT/CT-Saúde (grant 400949/2005–9), Brazil; Susan G Komen for the Cure (grant POP0403033); FAPERGS (grant PSUS 2006); and Fundo de Incentivo à Pesquisa do Hospital de Clínicas de Porto Alegre FIPE/HCPA (grant 05–182), Brazil.
Competing interests None.
Patient consent Obtained.
Provenance and Peer review Not commissioned; externally peer reviewed.